Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
life sciences
9
×
national blog main
clinical trials
boston blog main
fda
national top stories
boston top stories
san diego blog main
san diego top stories
san francisco blog main
boston
deals
investing
national
new york blog main
san francisco top stories
allergan
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
covid-19
detroit blog main
detroit top stories
drug delivery
eli lilly
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
What
treat
9
×
medicines
therapeutics
approved
developing
drug
fda
new
approval
biologics
biotech
diseases
ipo
late
million
raised
raises
therapy
way
abcellera
abcellera’s
abide
adults
advance
advanced
affects
agency
aimmune
allergan
allergy
alnylam’s
americans
analytics
antibodies
antibody
appointed
awarded
based
bff
bio
Language
unset
Current search:
biotech
×
treat
×
" life sciences "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President